Zydus Lifesciences Receives USFDA Approval For Norelgestromin and Ethinyl Estradiol Transdermal System

vThe United States Food and Drug Administration (USFDA) has granted final approval to Zydus Lifesciences for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day (USRLD: Ortho Evra Transdermal System, 150 mcg/35 mcg per day). Norelgestromin and Ethinyl Estradiol Transdermal System contains combination hormone medication and is used to prevent pregnancy.

This is the third hormonal transdermal patch to be approved from Zydus’ generics portfolio. The transdermal patch will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, as per EP News Bureau. In the United States, the Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day, had annual sales of $330 million. Zydus Lifesciences Limited, originally Cadila Healthcare Limited, is an Indian multinational pharmaceutical business based in Ahmedabad that mostly manufactures generic pharmaceuticals. In 2020, the company was rated 100th on the Fortune India 500 list.

We have grown and reinvented ourselves in response to changing times after a 27-year journey of growth as Cadila Healthcare Ltd. and the Zydus Group. Our new mission, vision, and purpose reinforce our tradition of almost 70 years in healthcare and dedication to life in all its dimensions. Cadila Healthcare Ltd. is renamed Zydus Lifesciences Ltd. after unifying under the Zydus brand.